Aviado · Research
Longevity Daily
Monday, August 3, 2026
Listen
Today's Brief
Today's issue is anchored by a striking Lancet Public Health finding: as lifespans grow longer, the share of years spent in poor health is actually rising — and the trend is worst in high-income countries. That sobering data sits alongside strong cognitive health news, including Phase 2 results for UCB's tau-targeting antibody bepranemab and the NYT's analysis of blood-based Alzheimer's screening edging toward Medicare coverage. A sweeping review of 350+ studies challenges the high-protein orthodoxy many longevity optimizers live by, and British Vogue brings a surprisingly rigorous reality check to the NAD+ precursor debate.
10 stories3 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
A New Blood Test Could Detect Alzheimer's Years Early — But Is America Ready?
A New York Times opinion piece examines the promise and peril of blood-based Alzheimer's screening, noting that Congress is already moving to authorize Medicare coverage via the bipartisan Alzheimer's Screening and Prevention Act. The upside is enormous — earlier detection means earlier intervention with the new generation of disease-modifying drugs. But serious questions remain about what patients and clinicians should actually do with a positive result before treatments are further proven.
Read more →Going to Community Gatherings Could Cut Your Risk of Cognitive Decline in Half
A new study found that older adults who regularly attended community gathering places had roughly half the four-year risk of developing cognitive disability compared to those who didn't — even after accounting for exercise habits. The benefit was especially pronounced for people who weren't getting regular physical activity, suggesting social engagement may independently protect the aging brain. If you're not already scheduling regular in-person social outings, consider this your scientific nudge.
Read more →UCB's Anti-Tau Antibody Bepranemab Slows Tau Buildup in Phase 2 TOGETHER Trial
In the Phase 2 TOGETHER trial, UCB's bepranemab — an antibody targeting the tau protein central to Alzheimer's progression — demonstrated meaningful slowing of tau accumulation in early-stage patients. This adds to a growing pipeline of tau-focused therapies that complement the amyloid-targeting drugs already on the market. Tau is increasingly seen as the key driver of cognitive decline once amyloid plaques have formed, making this a significant advance.
Read more →Supplements & Compounds
NAD+ or NMN: Which Supplement Actually Works for Aging? What the Evidence Really Says
British Vogue's health roundup takes a clear-eyed look at the NAD+ precursor market, with experts cautioning that 'human research remains limited' and that direct NAD+ infusions have not been proven superior to high-quality oral NMN supplements. Both approaches may raise NAD+ levels, but whether that translates to measurable anti-aging benefits in humans is still unresolved. For anyone spending serious money on IV NAD+ drips, this is a useful reality check.
Read more →Metformin's Longevity Case Gets Stronger: Gut Microbiome, Inflammation, and Caloric Restriction Mimicry
A Psychiatric Times review connects metformin's anti-aging potential to three converging mechanisms: mimicry of caloric restriction, favorable modulation of the gut microbiome, and systemic anti-inflammatory effects. The drug — already being studied in the landmark TAME longevity trial — appears to alter gut bacteria composition in ways that parallel healthspan-extending dietary interventions. For longevity-focused clinicians and patients, this review consolidates the case for metformin well beyond its diabetes roots.
Read more →Research & Papers
We're Living Longer — But Spending More Years Sick, Major Lancet Study Warns
A Lancet Public Health analysis finds that while global lifespans are extending, the proportion of life spent in poor health is rising, not falling — and the trend is sharpest in high-income countries. The data delivers a stark reframe of the longevity debate: adding years to life is largely meaningless if those years are defined by disease and disability. This is the core argument behind healthspan-focused medicine, and it now has Lancet-level data behind it. If you're optimizing for longevity, this is the study that explains exactly why healthspan — not lifespan — is the right target.
Read more →DNA Mutations Set a Hard Ceiling on Human Lifespan at 146–194 Years, Study Suggests
Researchers analyzing somatic DNA mutation rates have calculated that even under the most favorable biological conditions, human lifespan is likely capped at 146–194 years by the cumulative burden of genetic errors. The findings suggest there are aspects of aging that may ultimately prove impossible to fully reverse through intervention, no matter how advanced the medicine becomes. For longevity optimizers, this is less a discouragement than a clarification: the goal isn't immortality, it's maximizing healthy, functional years within that biological ceiling.
Read more →Aviado Research: Featured Analysis
Aviado Research's latest deep-dive examines the current evidence at the intersection of aging biology and actionable intervention. This analysis synthesizes recent findings with a practical lens, helping health optimizers distinguish signal from noise in a rapidly evolving field.
Read the full Aviado analysis →Lifestyle & Nutrition
350 Studies Later: Eating Less Protein May Actually Slow Aging
A sweeping review of more than 350 studies suggests the high-protein diet movement may be overselling its longevity benefits — and that moderate protein restriction may activate beneficial aging pathways including mTOR inhibition and improved metabolic flexibility. The findings directly challenge the protein-maximizing approach popular in performance and longevity communities. If you've been loading up on protein powders for anti-aging reasons, this review is worth a careful read before your next grocery order.
Read more →Industry & Policy
Genflow Biosciences Expands SIRT6 Patent Portfolio, Awaits First Dog Trial Results
Longevity biotech Genflow Biosciences (LSE: GENF) is expanding its intellectual property around SIRT6 gene therapy — the longevity gene found at elevated levels in centenarians — and expects to release results from its Age Dogs trial at the Animal Longevity Summit in Toronto. SIRT6 is one of the most validated longevity targets in the field, with animal studies showing meaningfully extended healthspan. Results from the canine trial will be a key signal for whether SIRT6 gene therapy can translate to larger mammals — and eventually humans.
Read more →